Results 71 to 80 of about 14,154 (120)

Patterns of HIV-1 Viral Load Suppression and Drug Resistance During the Dolutegravir Transition: A Population-based Longitudinal Study. [PDF]

open access: yesClin Infect Dis
Martin MA   +22 more
europepmc   +1 more source

The therapeutic potential of transposable element activity modulation. [PDF]

open access: yesEMBO Mol Med
Morelli G   +3 more
europepmc   +1 more source

Switching to doravirine-based antiretroviral therapy without genotypic resistance tests in virologically suppressed people with HIV. [PDF]

open access: yesAIDS
Mason J   +11 more
europepmc   +1 more source

Virologic, Lipid, Renal and Hepatic Laboratory Outcomes After Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Treatment-Experienced People with HIV: Real-World Evidence from the SHINe-SHIC Cohort. [PDF]

open access: yesInfect Dis Rep
Ceccarelli M   +14 more
europepmc   +1 more source

Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA. [PDF]

open access: yesJ Infect Dis
Diamond TL   +14 more
europepmc   +1 more source

Emerging Dolutegravir Resistance Among Children on Antiretroviral Therapy With Virological Failure in Malawi: Results From a 2023 National Cross-Sectional Survey. [PDF]

open access: yesJ Int AIDS Soc
Bello G   +25 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy